Evolent Health’s (EVH) Buy Rating Reiterated at BTIG Research

BTIG Research reissued their buy rating on shares of Evolent Health (NYSE:EVH) in a report released on Tuesday morning,Benzinga reports. The brokerage currently has a $20.00 price objective on the technology company’s stock.

Several other research firms also recently commented on EVH. Piper Sandler upped their price objective on shares of Evolent Health from $16.00 to $18.00 and gave the company an “overweight” rating in a report on Thursday, August 28th. Truist Financial upped their price objective on shares of Evolent Health from $14.00 to $16.00 and gave the company a “buy” rating in a report on Thursday, July 17th. JMP Securities reissued a “market outperform” rating and issued a $13.00 price target on shares of Evolent Health in a report on Friday, June 20th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $15.00 price target on shares of Evolent Health in a report on Tuesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $17.43.

Evolent Health Price Performance

NYSE EVH opened at $9.30 on Tuesday. The company has a market cap of $1.09 billion, a PE ratio of -5.78 and a beta of 0.73. Evolent Health has a 52 week low of $7.06 and a 52 week high of $31.80. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 0.72. The firm’s 50-day simple moving average is $9.88 and its two-hundred day simple moving average is $9.51.

Evolent Health (NYSE:EVH) last released its quarterly earnings data on Thursday, August 7th. The technology company reported ($0.10) EPS for the quarter, missing the consensus estimate of $0.10 by ($0.20). The business had revenue of $444.33 million for the quarter, compared to analysts’ expectations of $459.43 million. Evolent Health had a negative net margin of 5.94% and a positive return on equity of 1.83%. Evolent Health’s revenue for the quarter was down 31.3% compared to the same quarter last year. During the same period last year, the company earned $0.30 earnings per share. Evolent Health has set its Q3 2025 guidance at EPS. Research analysts predict that Evolent Health will post 0.08 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC grew its position in Evolent Health by 88.0% during the second quarter. Nisa Investment Advisors LLC now owns 2,551 shares of the technology company’s stock valued at $29,000 after acquiring an additional 1,194 shares during the last quarter. Parallel Advisors LLC grew its position in Evolent Health by 82.6% during the second quarter. Parallel Advisors LLC now owns 3,487 shares of the technology company’s stock valued at $39,000 after acquiring an additional 1,577 shares during the last quarter. Police & Firemen s Retirement System of New Jersey grew its position in Evolent Health by 10.8% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 27,242 shares of the technology company’s stock valued at $307,000 after acquiring an additional 2,666 shares during the last quarter. Banque Cantonale Vaudoise bought a new position in Evolent Health during the first quarter valued at approximately $25,000. Finally, Cetera Trust Company N.A grew its position in Evolent Health by 47.3% during the second quarter. Cetera Trust Company N.A now owns 9,725 shares of the technology company’s stock valued at $110,000 after acquiring an additional 3,125 shares during the last quarter.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.